Our coverage is unrivalled in its depth, geographic scope and local insights. We enable you to make informed and strategic decisions in an ever-changing and highly competitive market.
Our medical device intelligence covers 16 key therapy areas and is available through comprehensive device modules to offer clients complete flexibility of choice.
We produce thousands of quantitative and qualitative reports annually, instantly available, to help you make more informed decisions quickly.
Our Intelligence Centers offer constantly updated data, investigative news, analysis and tools that slot seamlessly into your workflow to help you decode the future.
For fully bespoke independent insight with dedicated expert service, our consulting offering combines global capabilities with strong understanding of your local markets.
Following Regeneron’s announcement that the FDA has accepted to review a supplemental biologics license application (sBLA) of Eylea for the treatment of diabetic retinopathy,
Following Friday’s announcement that Teva’s prophylactic migraine treatment, fremanezumab, received FDA approval,
Rahael Maladwala, Pharma Analyst at
Syphilis continues to be a global disease burden with a high and growing number of new cases each year with an estimated 1.2m incident cases forecast by 2027 in the 16 major markets (16MM*), accord...
contact online email@example.com
EMEA: +44 207 832 4399
APAC: +91 40 6616 6809
© GlobalData Plc 2018 | Registered Office: John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK Registered in England No. 03925319